

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 23, 2002, 14:38:33 ; Search time 29.8 Seconds  
(without alignments)  
697.007 Million cell updates/sec

Title: US-09-811-118-1

Perfect score: 187

Sequence: 1 MVAATVAAAWLLMAAACAAQ.....VRLQITAVRKLLIKREDL 187

Scoring table:  
Gapex 60.0, Gapext 60.0

Searched: 747574 seqs, 111073796 residues

Word size: 0

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database: A\_Geneseq\_032802.\*

1: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1980.DAT.\*  
2: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1981.DAT.\*  
3: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1982.DAT.\*  
4: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1983.DAT.\*  
5: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1984.DAT.\*  
6: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1985.DAT.\*  
7: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1986.DAT.\*  
8: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1987.DAT.\*  
9: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1988.DAT.\*  
10: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1989.DAT.\*  
11: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1990.DAT.\*  
12: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1991.DAT.\*  
13: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1992.DAT.\*  
14: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1993.DAT.\*  
15: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1994.DAT.\*  
16: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1995.DAT.\*  
17: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1996.DAT.\*  
18: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1997.DAT.\*  
19: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1998.DAT.\*  
20: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1999.DAT.\*  
21: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA2000.DAT.\*  
22: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	187	100.0	187	22	Human glutathione
2	104	55.6	187	21	Membrane-bound pro
3	104	55.6	187	22	Human PRO polypept
4	104	55.6	187	22	Human protein sequ
5	104	55.6	187	22	Human secreted pro
6	104	55.6	187	22	Human PRO828 (UNO4
7	104	55.6	187	22	Human polypeptide
8	104	55.6	195	22	Human colon cancer
9	104	55.6	196	21	Human secreted pro
10	19	10.2	19	22	Human 5' EST relat
11	10	5.3	149	21	Human 5' EST relat

12	10	5.3	209	21	AA18915
13	10	5.3	209	21	AA24484
14	10	5.3	209	21	AA29258
15	10	5.3	209	22	AA39735
16	10	5.3	217	22	AA41521
17	9	4.8	82	21	AA12348
18	9	4.8	108	21	AA24452
19	9	4.8	116	21	AA26942
20	9	4.8	117	21	AA16585
21	9	4.8	124	21	AA43426
22	9	4.8	125	21	AA25034
23	9	4.8	156	21	AA12346
24	9	4.8	160	21	AA26941
25	9	4.8	166	22	AAU04502
26	9	4.8	166	22	AAU04503
27	9	4.8	166	22	AAU04504
28	9	4.8	166	22	AAU04505
29	9	4.8	166	22	AAU04506
30	9	4.8	167	22	AAU04397
31	9	4.8	167	22	AAU04398
32	9	4.8	167	22	AAU04399
33	9	4.8	167	22	AAU04400
34	9	4.8	167	22	AAU04501
35	9	4.8	167	22	AAU04515
36	9	4.8	167	22	AAU04516
37	9	4.8	167	22	AAU04517
38	9	4.8	167	22	AAU04518
39	9	4.8	167	22	AAU04519
40	9	4.8	169	21	AA44988
41	9	4.8	169	21	AA19335
42	9	4.8	169	21	AA20980
43	9	4.8	169	21	AA23532
44	9	4.8	169	21	AA42765
45	9	4.8	21		

## ALIGNMENTS

RESULT 1	
ID	AA18915 standard; Protein; 187 AA.
XX	
AC	AA18915;
XX	
DT	29-OCT-2001 (first entry)
XX	
DE	Human glutathione peroxidase (GPx6) polypeptide.
XX	
XX	Glutathione peroxidase; GPx6; anti-human immunodeficiency virus; HIV;
KW	antifungal; antifungal; antifungal; antifungal; antifungal; antifungal;
KW	antigenic; antitumor; immunosuppressive; antidiabetic; nephrotropic;
KW	antigenic; neuroprotective; osteoprotective; antineoplastic; antitumor;
KW	transglutinin; vulvar; antidiabetic; antidiabetic; antidiabetic; human;
KW	antiproliferative; cytosolic.
XX	
OS	Homo sapiens.
XX	
PN	US6231853-B1.
PN	
PD	15-MAY-2001.
XX	
PF	01-JUN-1998; 98US-0088549.
XX	
PK	01-JUN-1998; 98US-0088549.
XX	
PA	(INCY-) INCYTE PHARM INC.
XX	
PI	Hillman JL, Corley NC, Patterson C;
XX	
DR	WPI, 2001-335067/35.
DR	N-PSDB; AA146980.
XX	



PR 02-JUL-1998; 98US-0091626.  
 PR 02-JUL-1998; 98US-0091628.  
 PR 02-JUL-1998; 98US-0091633.  
 PR 02-JUL-1998; 98US-0091646.  
 PR 02-JUL-1998; 98US-0091673.  
 PR 07-JUL-1998; 98US-0091978.  
 PR 09-JUL-1998; 98US-0091982.  
 PR 10-JUL-1998; 98US-0092182.  
 PR 20-JUL-1998; 98US-0093339.  
 PR 30-JUL-1998; 98US-0094651.  
 PR 04-AUG-1998; 98US-0095282.  
 PR 04-AUG-1998; 98US-0095285.  
 PR 04-AUG-1998; 98US-0095301.  
 PR 04-AUG-1998; 98US-0095302.  
 PR 04-AUG-1998; 98US-0095318.  
 PR 04-AUG-1998; 98US-0095321.  
 PR 04-AUG-1998; 98US-0095325.  
 PR 10-AUG-1998; 98US-0095916.  
 PR 10-AUG-1998; 98US-0095929.  
 PR 11-AUG-1998; 98US-0096012.  
 PR 11-AUG-1998; 98US-0096143.  
 PR 12-AUG-1998; 98US-0096146.  
 PR 12-AUG-1998; 98US-0096329.  
 PR 17-AUG-1998; 98US-0096757.  
 PR 17-AUG-1998; 98US-0096766.  
 PR 17-AUG-1998; 98US-0096773.  
 PR 17-AUG-1998; 98US-0096791.  
 PR 17-AUG-1998; 98US-0096867.  
 PR 17-AUG-1998; 98US-0096891.  
 PR 17-AUG-1998; 98US-0096894.  
 PR 17-AUG-1998; 98US-0096895.  
 PR 17-AUG-1998; 98US-0096897.  
 PR 18-AUG-1998; 98US-0096949.  
 PR 18-AUG-1998; 98US-0096950.  
 PR 18-AUG-1998; 98US-0096959.  
 PR 18-AUG-1998; 98US-0096960.  
 PR 18-AUG-1998; 98US-0097022.  
 PR 19-AUG-1998; 98US-0097141.  
 PR 20-AUG-1998; 98US-0097218.  
 PR 24-AUG-1998; 98US-0097661.  
 PR 26-AUG-1998; 98US-0097951.  
 PR 26-AUG-1998; 98US-0097952.  
 PR 26-AUG-1998; 98US-0097954.  
 PR 26-AUG-1998; 98US-0097955.  
 PR 26-AUG-1998; 98US-0097971.  
 PR 26-AUG-1998; 98US-0097974.  
 PR 26-AUG-1998; 98US-0097978.  
 PR 26-AUG-1998; 98US-0097979.  
 PR 26-AUG-1998; 98US-0097986.  
 PR 26-AUG-1998; 98US-0098014.  
 PR 31-AUG-1998; 98US-0098525.  
 PR 16-SEP-1998; 98US-0100634.  
 PR 12-JAN-1999; 99US-0115565.  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;  
 PI Wood WL, Yuan J;  
 XX  
 DR WPI; 2000-072883/06.  
 DR N-PSDB; AAZ65013.  
 XX  
 PT Membrane-bound proteins and related nucleotide sequences -  
 XX  
 PS claim 12; Fig 120; 822pp; English.  
 XX  
 CC The invention provides membrane-bound PRO polypeptides and  
 CC polynucleotides encoding them. The PRO sequences of the invention were  
 CC identified based on extracellular domain homology screening. The PRO  
 CC sequences have homology with proteins including LDL receptors, TIE  
 CC ligands and various enzymes. The membrane-bound proteins and receptor

CC molecules are useful as pharmaceutical and diagnostic agents. Receptor  
 CC immunoadhesins, for instance, can be used as therapeutic agents to block  
 CC receptor-ligand interactions. The membrane-bound proteins can also be  
 CC employed for screening of potential peptide or small molecule inhibitors  
 CC of the relevant receptor/ligand interaction. The PRO encoding sequences  
 CC are useful as hybridization probes, in chromosome and gene mapping and in  
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences  
 CC will also be useful for the preparation of PRO polypeptides, especially  
 CC by recombinant techniques.  
 XX  
 SQ Sequence 187 AA;  
 Query Match 55.6%; Score 104; DB 21; Length 187;  
 Best Local Similarity 100.0%; Pred No. 2.9e-100; Mismatches 0; Gaps 0;  
 Matches 104; Conservative 0; Indels 0;  
 QY 1 MVAATVAAAMLTLMAACAQOEODFYDFKAVNIRGLVLSLEKRGVSILVNVASCEGFT 60  
 DB 1 mvaatvaaaawlllwaacacagqegdfydfkavnlrgrlvslekyrgsvslvvnasecgtl 60  
 QY 61 DQHYRALQQLQRPDLGPHHENVLAFCPCNGQEQEPDSNKEIESFA 104  
 DB 61 dqhyralqqlqlgphhinvlaftpncfgyqgdpdsanketesfa 104  
 RESULT 3  
 AAU29236  
 ID AAU29236 standard; Protein; 187 AA.  
 XX  
 AC AAU29236;  
 XX  
 DT 18-DEC-2001 (first entry)  
 XX  
 DE Human PRO polypeptide sequence #213.  
 XX  
 KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;  
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;  
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;  
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.  
 OS Homo sapiens.  
 XX  
 PN WO200168848-A2.  
 XX  
 PD 20-SEP-2001.  
 XX  
 PF 28-FEB-2001; 2001WO-US06520.  
 XX  
 PR 01-MAR-2000; 2000WO-US05601.  
 PR 02-MAR-2000; 2000WO-US05841.  
 PR 03-MAR-2000; 2000US-187202P.  
 PR 06-MAR-2000; 2000US-186568P.  
 PR 14-MAR-2000; 2000US-189320P.  
 PR 14-MAR-2000; 2000US-189328P.  
 PR 15-MAR-2000; 2000WO-US06884.  
 PR 21-MAR-2000; 2000US-190828P.  
 PR 21-MAR-2000; 2000US-191007P.  
 PR 21-MAR-2000; 2000US-191048P.  
 PR 21-MAR-2000; 2000US-191314P.  
 PR 28-MAR-2000; 2000US-192655P.  
 PR 29-MAR-2000; 2000US-193032P.  
 PR 29-MAR-2000; 2000US-193053P.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 04-APR-2000; 2000US-194449P.  
 PR 04-APR-2000; 2000US-194647P.  
 PR 11-APR-2000; 2000US-195975P.  
 PR 11-APR-2000; 2000US-196000P.  
 PR 11-APR-2000; 2000US-196187P.  
 PR 11-APR-2000; 2000US-196690P.  
 PR 11-APR-2000; 2000US-196820P.  
 PR 18-APR-2000; 2000US-198121P.  
 PR 18-APR-2000; 2000US-198585P.

PR 25-APR-2000; 2000US-199397P.  
PR 25-APR-2000; 2000US-199550P.  
PR 25-APR-2000; 2000US-199654P.  
PR 03-MAY-2000; 2000US-201516P.  
PR 17-MAY-2000; 2000MO-US13705.  
PR 22-MAY-2000; 2000MO-US14042.  
PR 30-MAY-2000; 2000MO-US14941.  
PR 02-JUN-2000; 2000MO-US15264.  
PR 05-JUN-2000; 2000US-209832P.  
PR 28-JUL-2000; 2000MO-US20710.  
PR 22-AUG-2000; 2000US-0644848.  
PR 24-AUG-2000; 2000MO-US33328.  
PR 08-NOV-2000; 2000MO-US30952.  
PR 01-DEC-2000; 2000MO-US32678.  
PR 20-DEC-2000; 2000MO-US34956.  
XX  
XX (GENTH ) GENENTECH INC.  
XX  
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL,  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2001-602746/68.  
DR N-PSDB; AAS46137.  
XX  
PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the  
PT presence of tumours, such as prostate and breast tumours, in mammals and  
PT to screen for modulators of the compounds -  
XX  
PS Claim 11; Fig 426; 774pp; English.  
XX  
CC Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.  
CC The PRO polypeptides and their associated nucleic acids can be used to  
CC detect the presence of a tumour in a mammal by comparing the level of  
CC expression of a PRO polypeptide in a test sample of cells from the animal  
CC and a control sample of normal cells, whereby a higher level of  
CC expression in the test sample indicates the presence of a tumour in the  
CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats  
CC and rabbits but are preferably human. The polypeptides can be used to  
CC stimulate tumour necrosis factor (TNF) alpha release from human blood,  
CC when contacted with it. A specific polypeptide can be used to stimulate  
CC the proliferation or differentiation of chondrocyte cells. The PRO  
CC proteins can be used to determine the presence of tumours and also  
CC susceptibility to tumour development, particularly adrenal, lung, colon,  
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian  
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids  
CC can be used for genetic analysis of individuals with genetic disorders.  
XX  
XX Sequence 187 AA;  
SQ  
Query Match 55.6%; Score 104; DB 22; Length 187;  
Best Local Similarity 100.0%; Pred. No. 2.9e-100;  
Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MVAATVAAAMLMLMAACAQOEDFYDFKAVNIRGKLVSEKYGVSILVNVASCGFT 60  
DB 1 mvaatvaaaalllwaacacagqgdlydfkavnlrgklvsekygsvslvvnasecgft 60  
QY 61 DQHYRALQOLQRLDGRPHFNVLAFPCNQFGQOEPDSNKEIESFA 104  
DB 61 dqhyralqqlgrdlgrphfnvlfapcnqfgqgpepsdnkeiesfa 104  
XX  
XX RESULT 4  
XX AAM38871  
ID AAM38871 standard; Protein: 187 AA.  
XX  
XX AAM38871;  
XX  
XX 22-OCT-2001 (first entry)  
XX  
XX Human polypeptide SEQ ID NO 2016.  
XX

KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokine; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia.  
XX  
XX Homo sapiens.  
XX  
XX WO200153312-A1.  
XX  
XX 26-JUL-2001.  
XX  
XX 26-DEC-2000; 2000MO-US34263.  
XX  
XX 21-JAN-2000; 2000US-0488725.  
XX 25-APR-2000; 2000US-0552317.  
XX 09-JUL-2000; 2000US-0598042.  
XX 19-JUL-2000; 2000US-0620312.  
XX 03-AUG-2000; 2000US-0653450.  
XX 14-SEP-2000; 2000US-0662191.  
XX 19-OCT-2000; 2000US-0693036.  
XX 29-NOV-2000; 2000US-0727344.  
XX  
XX (HYSE-) HYSEQ INC.  
XX  
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;  
XX  
XX WPI; 2001-442253/47.  
DR N-PSDB; AA158027.  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries -  
XX  
XX Example 3; SEQ ID NO 2016; 10078pp; English.  
XX  
XX The invention relates to human nucleic acids (AA157798-AA161369) and  
XX the encoded polypeptides (AAM38642-AA42213) with nootropic,  
XX immunosuppressant and cytostatic activity. The polynucleotides are useful  
XX in gene therapy. A composition containing a polypeptide or polynucleotide  
XX of the invention may be used to treat diseases of the peripheral nervous  
XX system, such as peripheral nervous injuries, peripheral neuropathy and  
XX localised neuropathies and central nervous system diseases, such as  
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
XX utilisation of the activities such as: Immune system suppression,  
XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
XX assays for receptor activity, arthritis and inflammation, leukaemias and  
XX C.N.S disorders.  
XX Note: The sequence data for this patent did not form part of the printed  
XX specification.  
XX  
XX Sequence 187 AA;  
SQ  
Query Match 55.6%; Score 104; DB 22; Length 187;  
Best Local Similarity 100.0%; Pred. No. 2.9e-100;  
Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MVAATVAAAMLMLMAACAQOEDFYDFKAVNIRGKLVSEKYGVSILVNVASCGFT 60  
DB 1 mvaatvaaaalllwaacacagqgdlydfkavnlrgklvsekygsvslvvnasecgft 60  
QY 61 DQHYRALQOLQRLDGRPHFNVLAFPCNQFGQOEPDSNKEIESFA 104  
DB 61 dqhyralqqlgrdlgrphfnvlfapcnqfgqgpepsdnkeiesfa 104  
XX  
XX RESULT 5  
XX AAB93154



specific cells, to cause tar

PI	Yang YT,	Liu C,	Asundi V,	Chen R,	Ma Y,	Qian XB,	Ren F,	Wang D,
PI	Wang J,	Wang Z,	Webbman T,	Yu C,	Yu H,	Yu H,	Yu H,	Yu H,

PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

XX	WPI: 2001-442253/47.
DR	N-PsDB: AAI59813.
XX	
PT	Novel nucleic acids and polypeptides, useful for treating disorders
PT	such as central nervous system injuries -
PS	
XX	
XX	Example 2: SEQ ID NO 5588; 10078bp; English.
CC	
CC	The invention relates to human nucleic acids (AA157796-AA161369) and
CC	the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC	immunosuppressant and cytostatic activity. The polynucleotides are useful
CC	in gene therapy. A composition containing a polypeptide or polynucleotide
CC	of the invention may be used to treat diseases of the peripheral nervous
CC	system, such as peripheral nervous injuries, peripheral neuropathy and
CC	localised neuropathies and central nervous system diseases, such as
CC	Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC	lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC	utilisation of the activities such as: Immune system suppression,
CC	Activin/Inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC	and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC	assays for receptor activity, arthritis and inflammation, leukaemias and
CC	C.N.S. disorders.
CC	Note: The sequence data for this patent did not form part of the printed
CC	specification.
CC	
XX	
SQ	Sequence 195 AA;
	Query Match 55.6%; Score 104; DB 22; Length 195;
	Best Local Similarity 100.0%; Pred. No. 3e-100;
	Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
QY	1 MVAATVAAAMLILLMAACAQCEQDEYDFEKAVNIRKIVSLEKYSVSLVWVNASPCGPT 60
DB	9 mvaatvaawlllwaaacqgqgdtydfkavnlrklvslkyrgsvslvvnvasecgft 68
OY	61 DQHYRALQQLQRLDGLPHHFNVLAFPCNQGFGQEPDSNKEISFPA 104
DB	69 dqhyralqqlgrdlqphhfnvnlafpcnqfgqgqepsnkeiesfa 112
RESULT 9	
AAB53468	
ID	AAB53468 standard; Protein; 196 AA.
XX	
AC	AAB53468;
XX	
DT	09-MAR-2001 (first entry)
XX	
DE	Human colon cancer antigen protein sequence SEQ ID NO:1008.
XX	
KW	Human: colon cancer; colon cancer antigen; diagnosis; detection;
KW	identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW	immunomodulatory; muscular; gynaecological; gastrointestinal;
KW	neurotropic; antiinfective; antibacterial; gene therapy; wound;
KW	neural disorder; immune system disorder; muscular disorder;
KW	reproductive disorder; gastrointestinal disorder; renal disorder;
KW	infectious disease; cardiovascular disorder.
XX	
OS	Homo sapiens.
XX	
PN	WO200055351-A1.
PD	
XX	21-SEP-2000.
XX	
PF	08-MAR-2000; 2000WO-US05883.
XX	
PR	12-MAR-1999; 99US-0124270.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
XX	
PI	Rosen CA, Ruben SM;

XX	WPI, 2000-587534/55.
DR	N-PSDB; AAC98225.
XX	
PT	Colon cancer associated gene sequences, referred to as colon cancer
PT	antigens, useful for the treatment, prevention, and diagnosis of colon
PT	disorders such as colon cancer -
XX	
XX	Claim 11; Page 1592: 2104pp; English.
PS	
XX	
CC	AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC	called human colon cancer antigens, given in AAB55234 to AAB54006. The
CC	human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC	neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC	vulnerability, nephrotoxic, anti-infective and antibacterial activities, and
CC	can be used in gene therapy. The colon cancer antigen polynucleotides,
CC	proteins and antibodies to the proteins are useful for the prevention,
CC	treatment and diagnosis of colon disorders, such as colon cancer. The
CC	polynucleotides may be used in diagnostics and research, such as for
CC	chromosome identification, and as hybridisation probes. The proteins
CC	may also be used to prevent diseases such as neural disorders, immune
CC	system disorders, muscular disorders, reproductive disorders,
CC	gastrointestinal disorders, wounds, renal disorders, infectious
CC	diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC	AAB54007 represent sequences used in the exemplification of the present
CC	invention.
CC	
XX	
SQ	Sequence 196 AA:
	Query Match 55.6%; Score 104; DB 21; Length 196;
	Best Local Similarity 100.0%; Pred. No. 3e-100;
	Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 MAAATVAAAMLTLMAAAGCQEDDYDFFAVNIIRGLVSLKRYGVSILVNVASPCGT 60
Db	10 mwaatvaawmlllwaacagqeqdlydfkavniirglvslkyrgvsilvnvascgtf 69
OY	61 DQHYRALQQLRDLDGPHHFNVLAFPCNFGQGDPPDSNKKEIESFA 104
Db	70 dqhyralqqlgrdlgphtfnvlafcnfgqgdpsnsksiesfa 113
	RESULT 10
ID	AAB74764
XX	AAB74764 standard; Protein; 19 AA.
AC	AAB74764;
XX	
DT	12-JUN-2001 (first entry)
XX	
DE	Human secreted protein sequence encoded by gene 2 SEQ ID NO:73.
XX	
KM	Human; secreted protein; diagnosis; immunomodulatory; antisclerotic;
KM	dermatological; immunosuppressive; anti-inflammatory; anti-HIV;
KM	immunostimulant; cytosstatic; cardiant; vascular; anti-angiogenic;
KM	ophthalmeologic; neuroprotectant; nootrophic; anticoagulant; vaccine;
KM	anti-alzheimer; anti-parkinsonian; antimicrobial; vulnerary; gene therapy;
KM	immune disorder; hyperproliferative disorder; cardiovascular disease;
KM	cancer; angiogenic disorder; neurological disorder; infectious disease;
KM	wound healing; regeneration; chemotaxis.
XX	
OS	Homo sapiens.
PN	WO200112775-A2.
XX	
PD	22-FEB-2001.
XX	
PF	16-AUG-2000; 2000MO-US22325.
XX	
PR	17-AUG-1999; 99US-0149182.
XX	
PA	(HUMA-) HUMAN GENOME SCT INC.

```

XX  Rosen CA, Ni J, Florence KA, Fiscella M, Wei P, Baker KP:
PI  Birse CE, Young PE, Komatsoulis GA, Moore PA, Soppet DR:
XX  WPI: 2001-147550/15.
DR  Nucleic acids encoding 25 human secreted polypeptides, useful for
XX  preventing, diagnosing and/or treating e.g. cancers, Parkinson's
XX  disease and diabetic retinopathy -
PS  Disclosure: Page 14; 485pp; English.
XX  AAF81787 to AAF81817 encode the human secreted proteins given in AAB74733
CC  to AAB74772. Human secreted proteins can have activities based on the
CC  tissues and cells they are expressed in. Example of activities include:
CC  immunomodulatory; antisclerotic; dermatological; immunosuppressive;
CC  antiinflammatory; anti-HIV; immunostimulant; cytoskeletal; cardiac;
CC  vascular; anti-angiogenic; ophthalmological; neuroprotectant; nootropic;
CC  anticonvulsant; antialzheimers; antiparkinsonian; antimicrobial; and
CC  vulnervary. Human secreted protein nucleotide sequences (NAMI) and proteins
CC  (PEPI) may be used in the prevention, diagnosis and treatment of diseases
CC  associated with inappropriate polypeptide expression. For example, NAMI
CC  and PEPI may be used to treat disorders associated with decreased
CC  expression by rectifying mutations or deletions in a patients genome
CC  that affect the activity of proteins by expressing inactive proteins or
CC  to supplement the activity of proteins own production of polypeptides. Disorders that
CC  may be prevented, diagnosed and/or treated include immune disorders,
CC  hyperproliferative disorders (e.g. cancers), cardiovascular diseases,
CC  angiogenic disorders, neurological disorders, infectious diseases and/or
CC  for promoting wound healing, regeneration and/or chemotaxis. AAF81778 to
CC  AAF81786 and AAB74732 represent sequences used in the exemplification of
CC  the present invention.
XX  SQ  Sequence 19 AA:
XX  Query Match 10.2%; Score 19; DB 22; Length 19;
XX  Best Local Similarity 100.0%; Pred. No. 1.9e-12;
XX  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  78 HFNVLAFPCNOFGOODEPDS 96
DB  1 hfnvlaifpcngf9gqepds 19
RESULT 11
ID  AAY65356 standard; Protein; 149 AA.
XX  AAY65356;
AC  AAY65356;
XX  01-FEB-2000 (first entry)
DT  01-FEB-2000 (first entry)
XX  Human 5' EST related polypeptide SEQ ID NO:1517.
DE  Human 5' EST; expressed sequence tag; secreted protein; diagnosis;
XX  Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;
XX  gene therapy; chromosome mapping; upstream regulatory sequence;
XX  forensic; location; development; protein synthesis; stability;
XX  regulation; identification.
XX  Homo sapiens.
XX  OS  Homo sapiens.
XX  FN  W09953051-A2.
XX  PD  21-OC7-1999.
XX  09-APR-1999; 99WO-IB00712.
XX  09-APR-1998; 98US-0057719.
XX  28-APR-1998; 98US-0069047.
XX  (GSET ) GENSET.
PA

```

```

XX  Dumas Milne Edwards J, Duclert A, Giordano J;
PI  WPI: 2000-038446/03.
XX  N-PSDB; AA242970.
DR  Novel secreted protein 5' expressed sequence tag sequences used in
XX  diagnostic, forensic, gene therapy, and chromosome mapping procedures
XX  Claim 3; Page 808; 837pp; English.
XX  AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)
CC  sequences, corresponding to human secreted proteins. AAY64651 to
CC  AAY65438 represent the EST-related proteins corresponding to AA242265 to
CC  AA243052. The 5' ESTs can be used for producing secreted human gene
CC  products. They can be used to identify and isolate 5' untranslated
CC  regions (UTRs) and upstream regulatory regions which control the
CC  location, development stage, rate, and quantity of protein synthesis, as
CC  well as stability of mRNA. The ESTs are also useful as probes for
CC  chromosome mapping, and to obtain full length cDNA clones. The ESTs can
CC  also be used in forensic procedures to identify individuals, or in
CC  diagnostic procedures to identify individuals having genetic diseases
CC  resulting from abnormal gene expression. The products may also be used in
CC  gene therapy protocols. The nucleic acids encoding signal peptides can be
CC  used for directing extracellular secretion of a polypeptide or the
CC  insertion of a polypeptide into a membrane, or importing a polypeptide
CC  into a cell. The proteins encoded by the EST sequences may be useful in
CC  treating a variety of human conditions. Secreted proteins have
CC  therapeutic value, and the identification of new secreted proteins is
CC  valuable. AA242249 to AA242264 and AAY64644 to AAY64650 represent
CC  sequences used in the exemplification of the present invention.
XX  SQ  Sequence 149 AA:
XX  Query Match 5.3%; Score 10; DB 21; Length 149;
XX  Best Local Similarity 100.0%; Pred. No. 0.028;
XX  Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  81 VLAFCNOFG 90
DB  103 vlaifpcngf 112
RESULT 12
ID  AAB18915 standard; Protein; 209 AA.
XX  AAB18915;
AC  AAB18915;
XX  08-FEB-2001 (first entry)
DT  08-FEB-2001 (first entry)
XX  A novel polypeptide designated PRO1785.
DE  A novel polypeptide designated PRO1785.
XX  Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
XX  PRO1889; PRO1890; PRO1785; PRO4353; PRO4405; PRO4356;
XX  PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
XX  PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
XX  insulinemia; kidney disorder; Bergers disease; nephropathy;
XX  Schonelein-Henoch purpura; celliac disease; dermatitis herpetiformis;
XX  Crohns disease.
XX  Homo sapiens.
XX  OS  Homo sapiens.
XX  FN  Key
XX  FT  Peptide
XX  FT  Location/Qualifiers
XX  FT  1..31
XX  FT  /note= "signal peptide"
XX  FT  MISC-difference 118
XX  FT  /note= "Asp encoded by CCA"
XX  PN  W0200056889-A2.
XX  28-SEP-2000.
XX  PD

```



[illegible]

```
DE Human secreted protein sequence encoded by gene 16 seq ID NO:109.
XX
KW Human; secreted protein; cytosolic; antianaemic; antidiabetic;
KW antiinflammatory; ophthalmological; antirheumatic; antiarthritic;
KW antiproliferative; angiogenesis; cardiant; anti-HIV; neotrophic;
KW neuroprotective; antimicrobial; antiparkinsonian; cancer;
KW immune system disorder; angiogenesis; hyperproliferative disorder;
KW cardiovascular disorder; apoptosis; neurological disease;
KW infectious disease; wound healing; chromosome 5.
XX
OS Homo sapiens.
PN WO20035937-A1.
PD 22-JUN-2000.
XX
PF 16-DEC-1999; 99WO-US29950.
XX
PR 17-DEC-1998; 98US-0112809.
PR 18-DEC-1998; 98US-0113006.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PI Ruben SM, Edner R, Rosen CA, Endress GA, Soppet DR, Ni J;
PI Duan DR, Moore PA, Shi Y, Lafleur DW, Olsen HS, Florence K;
XX
DR WPI: 2000-431566/37.
DR N-PSTB; AAA78428.
XX
PT Forty seven human nucleic acids encoding secreted proteins, useful in
PT the treatment, prevention and diagnosis of cancers, disorders of the
PT immune system, angiogenesis disorders, neurological diseases and
PT hyperproliferative disorders -
XX
PS Claim 11; Page 523-524; 562pp; English.
XX
CC The polynucleotide sequence given in AAB78381 to AAU78432 encode the
CC human secreted proteins given in AAB24437 to AAB24604. Human secreted
CC proteins have activities based on the tissues and cells the genes are
CC expressed in. Examples of activities include: cytostatic; antianaemic;
CC antidiabetic; antiinflammatory; ophthalmological; antirheumatic;
CC antiarthritic; antisporadic; angiogenic; cardiant; anti-HIV;
CC neotrophic; neuroprotective; antimicrobial and antiparkinsonian.
CC Human secreted protein polynucleotides, polypeptides, antagonists and/or
CC agonists may be useful in treating, preventing, and/or diagnosing other
CC diseases, disorders, and/or conditions such as: (a) cancers; (b)
CC hyperproliferative disorders; (c) angiogenesis disorders; (d)
CC disorders of the immune system; (e) cardiovascular disorders; (f) diseases
CC associated with increase apoptosis; (g) neurological diseases; and
CC (h) infectious diseases. They are also used to promote wound healing.
CC AAU78372 to AAU78380 and AAB24436 represent sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 209 AA:
OY 81 VLAFCNQGFG 90
DB 103 vlafpcngfg 112
Query Match 5.3%; Score 10; DB 21; Length 209;
Best Local Similarity 100.0%; Pred. No. 0.037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RESULT_14
AAU29258
ID AAU29258 standard; Protein: 209 AA.
XX
AC AAU29258;
XX
XX 18-DEC-2001 (first entry)
XX
```

DE Human PRO polypeptide sequence #235.  
 XX  
 KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;  
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;  
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;  
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.  
 OS Homo sapiens.  
 XX  
 PN WO200168848-A2.  
 PD  
 PD 20-SEP-2001.  
 XX  
 XX 28-FEB-2001; 2001WO-US06520.  
 XX  
 PR 01-MAR-2000; 2000WO-US05601.  
 PR 02-MAR-2000; 2000WO-US05841.  
 PR 03-MAR-2000; 2000US-187202P.  
 PR 06-MAR-2000; 2000US-186968P.  
 PR 14-MAR-2000; 2000US-189320P.  
 PR 14-MAR-2000; 2000US-189328P.  
 PR 15-MAR-2000; 2000WO-US06884.  
 PR 21-MAR-2000; 2000US-190828P.  
 PR 21-MAR-2000; 2000US-191007P.  
 PR 21-MAR-2000; 2000US-191048P.  
 PR 21-MAR-2000; 2000US-191314P.  
 PR 28-MAR-2000; 2000US-192655P.  
 PR 29-MAR-2000; 2000US-193032P.  
 PR 29-MAR-2000; 2000US-193053P.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 04-APR-2000; 2000US-194449P.  
 PR 11-APR-2000; 2000US-194647P.  
 PR 11-APR-2000; 2000US-195975P.  
 PR 11-APR-2000; 2000US-196000P.  
 PR 11-APR-2000; 2000US-196187P.  
 PR 11-APR-2000; 2000US-196690P.  
 PR 18-APR-2000; 2000US-196820P.  
 PR 18-APR-2000; 2000US-198121P.  
 PR 25-APR-2000; 2000US-198585P.  
 PR 25-APR-2000; 2000US-199397P.  
 PR 25-APR-2000; 2000US-199550P.  
 PR 03-MAY-2000; 2000US-199654P.  
 PR 17-MAY-2000; 2000US-201516P.  
 PR 22-MAY-2000; 2000WO-US13705.  
 PR 30-MAY-2000; 2000WO-US14042.  
 PR 02-JUN-2000; 2000WO-US14941.  
 PR 05-JUN-2000; 2000US-209832P.  
 PR 28-JUL-2000; 2000WO-US20710.  
 PR 22-AUG-2000; 2000US-0644848.  
 PR 24-AUG-2000; 2000WO-US23328.  
 PR 08-NOV-2000; 2000WO-US30952.  
 PR 01-DEC-2000; 2000WO-US32678.  
 PR 20-DEC-2000; 2000WO-US34956.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI; 2001-602746/68.  
 DR N-PSDB; AAS46159.  
 XX  
 PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the  
 PT presence of tumours, such as prostate and breast tumours, in mammals and  
 PT to screen for modulators of the compounds -  
 XX  
 PS Claim 11; Fig 470; 774pp; English.  
 CC Sequences AAN29024-AAU29328 represent PRO polypeptides of the invention.  
 CC The PRO polypeptides and their associated nucleic acids can be used to  
 CC detect the presence of a tumour in a mammal by comparing the level of  
 CC expression of a PRO polypeptide in a test sample of cells from the animal

CC and a control sample of normal cells, whereby a higher level of  
 CC expression in the test sample indicates the presence of a tumour in the  
 CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats  
 CC and rabbits but are preferably human. The polypeptides can be used to  
 CC stimulate tumour necrosis factor (TNF) alpha release from human blood,  
 CC when contacted with it. A specific polypeptide can be used to stimulate  
 CC the proliferation or differentiation of chondrocyte cells. The PRO  
 CC proteins can be used to determine the presence of tumours and also  
 CC susceptibility to tumour development, particularly adrenal, lung, colon,  
 CC breast, prostate, rectal, cervical, or liver tumours, in mammalian  
 CC subjects. The oligonucleotide probes specific for the PRO nucleic acids  
 CC can be used for genetic analysis of individuals with genetic disorders.  
 XX  
 SQ Sequence 209 AA;  
 XX  
 Query Match 5.3%; Score 10; DB 22; Length 209;  
 Best Local Similarity 100.0%; Pred. NO. 0.037;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 81 VLAFCNQFG 90  
 Db 103 vlafcngf 112  
 |||||  
 RESULT 15  
 AAM39735  
 ID AAM39735 standard; Protein; 209 AA.  
 XX  
 AC AAM39735;  
 XX  
 DT 22-OCT-2001 (first entry)  
 XX  
 DE Human polypeptide SEQ ID NO 2880.  
 XX  
 KW Human; neotropic; immunosuppressant; cytostatic; gene therapy; cancer;  
 KW peripheral nervous system; neuropathy; central nervous system; CNS;  
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; Chemotactic;  
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
 KW leukaemia.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200153312-A1.  
 XX  
 PD 26-JUL-2001.  
 XX  
 PF 26-DEC-2000; 2000WO-US34263.  
 XX  
 PR 21-JAN-2000; 2000US-0488725.  
 PR 25-APR-2000; 2000US-0552317.  
 PR 09-JUL-2000; 2000US-0598042.  
 PR 19-JUL-2000; 2000US-0620312.  
 PR 03-AUG-2000; 2000US-0653450.  
 PR 14-SEP-2000; 2000US-0662191.  
 PR 19-OCT-2000; 2000US-0693036.  
 PR 29-NOV-2000; 2000US-0727344.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 XX  
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;  
 DR WPI; 2001-442253/47.  
 DR N-PSDB; AAI58891.  
 XX  
 PT Novel nucleic acids and polypeptides, useful for treating disorders  
 PT such as central nervous system injuries -  
 XX  
 PS Example 4; SEQ ID NO 2880; 10078pp; English.  
 XX

CC The invention relates to human nucleic acids (AA157798-AA161369) and  
 CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
 CC in gene therapy. A composition containing a polypeptide or polynucleotide  
 CC of the invention may be used to treat diseases of the peripheral nervous  
 CC system, such as peripheral nervous injuries, peripheral neuropathy and  
 CC localised neuropathies and central nervous system diseases, such as  
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
 CC utilisation of the activities such as: Immune system suppression,  
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
 CC assays for receptor activity, arthritis and inflammation, leukaemias and  
 CC C.N.S disorders.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification.

XX  
 SQ Sequence 209 AA:

Query Match

Best Local Similarity 5.3%; Score 10; DB 22; Length 209;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 VLAFCNORG 90  
 |||||  
 Db 103 vlafpncgfg 112

Search completed: August 23, 2002, 14:40:53  
 Job time: 140 sec

